로그인
보증업체
스포츠중계
스포츠분석
먹튀사이트
지식/노하우
판매의뢰
업체홍보/구인
뉴스
커뮤니티
포토
포인트
보증카지노
보증토토
보증홀덤
스포츠 중계
기타
축구
야구
농구
배구
하키
미식축구
카지노 먹튀
토토 먹튀
먹튀제보
카지노 노하우
토토 노하우
홀덤 노하우
기타 지식/노하우
유용한 사이트
제작판매
제작의뢰
게임
구인
구직
총판
제작업체홍보
실시간뉴스
스포츠뉴스
연예뉴스
IT뉴스
자유게시판
유머★이슈
동영상
연예인
섹시bj
안구정화
출석하기
포인트 랭킹
포인트 마켓
로그인
자동로그인
회원가입
정보찾기
뉴스
더보기
[실시간뉴스]
송파 개표소 앞 농성 나흘째...투표함 반출 난항
N
[IT뉴스]
김택진 엔씨 대표, 젠슨 황 회동…25주년 동맹 기념해 PC방에서 만나
N
[IT뉴스]
네이버·엔비디아 'AI 동맹' 확대, 기가와트급 AI 팩토리 만든다
N
[IT뉴스]
엔비디아 협력사 에이로봇과 휴머노이드 실증하는 한화오션 [only 이데일리]
N
[IT뉴스]
국내 최초 소방전문병원 개원…“소방공무원 건강·안전 책임질 것”
N
커뮤니티
더보기
[자유게시판]
드디어 금요일이군요
[자유게시판]
오늘 다저스 어떻게 생각하시나요
[자유게시판]
하아 댓노
[자유게시판]
식곤증지립니다요
[자유게시판]
벌써 불금이네요
목록
글쓰기
[IT뉴스]D&D Pharmatech Rises on Big Deal Hopes; Aimed Bio, ImmuneOncia Slide[K-Bio Pulse]
온카뱅크관리자
조회:
8
2026-06-08 08:07:31
<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> <section dmcf-sid="ZxSVtEIksG"> <div contents-hash="fd5be78dbea6b1cc43ec3d15fa802f24ac99216b8b54c218a1e826ace7d72f62" dmcf-pid="5MvfFDCEmY" dmcf-ptype="general"> <div> This article was released as <strong>Pharm Edaily Premium Content</strong> on June 5, 2026, at 8:38 AM. </div> </div> <p contents-hash="685868634c8e5c5292f4ded4c0a282cdd9346f3faa8539f9bcea7b4f0260e353" dmcf-pid="1RT43whDOW" dmcf-ptype="general">[Kim Saemi, Edaily Reporter] D&D Pharmatech Inc. stood out in a weak biotech market on June 4, surging on expectations for a potential licensing deal in metabolic dysfunction-associated steatohepatitis (MASH). Aimed Bio Inc., by contrast, tumbled on concerns over a six-month post-listing lock-up expiry, while ImmuneOncia Therapeutics Inc. came under heavy selling pressure after its shares fell below the final issue price for its rights offering.</p> <figure class="figure_frm origin_fig" contents-hash="0e74ef81a33457985628da13b77bd53d055c7037140f6d90741a2e200dc2265d" dmcf-pid="tUa5OxnQry" dmcf-ptype="figure"> <p class="link_figure"><img alt="D&D Pharmatech CEO Seulki Lee introduces DD01 at the J.P. Morgan Healthcare Conference held in San Francisco in January. (Source: Edaily DB)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202606/08/Edaily/20260608080400030jqjk.jpg" data-org-width="800" dmcf-mid="XRFi9TZvOH" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202606/08/Edaily/20260608080400030jqjk.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> D&D Pharmatech CEO Seulki Lee introduces DD01 at the J.P. Morgan Healthcare Conference held in San Francisco in January. (Source: Edaily DB) </figcaption> </figure> <p contents-hash="ef7bca0379c798793ad7e59e742bf3f796413215fda712c82935f52037bcc366" dmcf-pid="FuN1IMLxrT" dmcf-ptype="general"><strong>D&D Pharmatech gains on MASH big deal hopes, CEO set to present data</strong></p> <p contents-hash="335a1bc4d52b7b61e6b8216b39ed724c75008e5a1a34ca4230841ba627e79394" dmcf-pid="37jtCRoMwv" dmcf-ptype="general">According to KG Zeroin’s MP DOCTOR, formerly Marketpoint, D&D Pharmatech closed at 94,000 won, up 9,900 won, or 11.77%, from the previous session.</p> <p contents-hash="6ec65343dd3a3121412f07a7e5869204962a8960952c410524e3aebbe2b92f5e" dmcf-pid="0zAFhegRES" dmcf-ptype="general">D&D Pharmatech held an investor relations session the same day to present 48-week biopsy results from its Phase 2 MASH trial of Zabopegdutide, also known by its development code DD01. The stock’s gains appear to have been driven by rising expectations for a licensing deal after the company said the drug achieved statistical significance across three key endpoints.</p> <p contents-hash="f2b057c809db63e6c2e833c6fd841c27d3cc162e6252e529fa9480a1d0af4499" dmcf-pid="pqc3ldaeOl" dmcf-ptype="general">D&D Pharmatech, in particular, highlighted a string of recent global MASH deals as evidence that it may be able to secure favorable licensing terms with a major pharmaceutical company.</p> <p contents-hash="d980be82cae52019283246ec96c09c0e8dedb3dd444044bdc1f24d4ca9b93e49" dmcf-pid="UBk0SJNdrh" dmcf-ptype="general">For example, GSK agreed in May last year to acquire Boston Pharmaceuticals’ MASH candidate efimosfermin in a deal worth up to $2 billion. Roche signed a deal in September last year to acquire 89bio’s pegozafermin, then in Phase 3 development, for up to $3.5 billion. Novo Nordisk followed in October with an agreement to acquire Akero Therapeutics’ Phase 3-stage efruxifermin for up to $5.2 billion.</p> <p contents-hash="ab54d5c496d837130f866100a5515812daec5615681892c395b7f7802ed8e7af" dmcf-pid="ubEpvijJIC" dmcf-ptype="general">D&D Pharmatech’s confidence appears to stem from DD01’s favorable biopsy data versus competing candidates. According to the company’s IR materials, DD01 achieved statistical significance in three key biopsy endpoints: MASH resolution without worsening of fibrosis, fibrosis improvement without worsening of MASH, and the composite endpoint of both MASH resolution and fibrosis improvement. Based on these results, the company said DD01 has competitiveness equal to or greater than recently acquired FGF21-class candidates.</p> <p contents-hash="0829953aaac58a7d3482e8fedc02e506693c6625a8c5ae2516d80522e7d09822" dmcf-pid="7KDUTnAirI" dmcf-ptype="general">News that D&D Pharmatech CEO Seulki Lee will personally attend and present at a briefing hosted by Kiwoom Securities on June 11 in Yeongdeungpo-gu, Seoul, to discuss the Phase 2 MASH results also appears to have partly contributed to the stock’s rise.</p> <p contents-hash="6b26f679769354c08062e30dcfdd78723f871ef74174bb5cb92c2b2ec46d107f" dmcf-pid="zPh95csAmO" dmcf-ptype="general">“At today’s IR session, we mainly provided a detailed explanation of data that had already been disclosed,” a D&D Pharmatech official said. “At the June 11 briefing, CEO Lee will attend and plans to disclose various additional information.”</p> <p contents-hash="8e1bbe1a15e51fc0496e3ad8e8b08712fec73de9901221bbc2e890465ff4dd66" dmcf-pid="qQl21kOcrs" dmcf-ptype="general"><strong>Aimed Bio drops as six-month lock-up expiry revives overhang concerns</strong></p> <p contents-hash="2e2f66bef11765949659f3f162f0d417fc8b3083cb6bd2d555baee508ca477e3" dmcf-pid="BxSVtEIkEm" dmcf-ptype="general">Aimed Bio, an antibody-drug conjugate (ADC) developer, plunged on concerns over shares released from lock-up six months after its listing.</p> <p contents-hash="199d695c4785429dfb508a1c82e9f10064201b5c8db92214da98208329de82ed" dmcf-pid="bMvfFDCEmr" dmcf-ptype="general">Aimed Bio, which listed in December last year, closed at 27,700 won, down 6,050 won, or 17.93%, from the previous session. The decline is interpreted as the result of renewed overhang concerns following the release of shares subject to six-month lock-up restrictions.</p> <p contents-hash="3e84749fe710a564bb6e249087253cc1acbc6cec56518c4b020d063df00620f7" dmcf-pid="KRT43whDIw" dmcf-ptype="general">The company’s six-month mandatory holding period expired that day. According to the Korea Securities Depository, 885,411 Aimed Bio shares were released from mandatory holding registration. However, based on the IPO share distribution table, the total number of shares eligible for release at the six-month mark, including shares held by existing shareholders and institutional investors under lock-up commitments, was about 5.29 million shares, equivalent to 8.25% of the company’s total listed shares.</p> <p contents-hash="87d2c9fe943a60a2f3e87d3e65d26916f5cadf74732119357b9416913661bca7" dmcf-pid="9ey80rlwED" dmcf-ptype="general">As the stock remains well above its IPO price of 11,000 won, the possibility of profit-taking by financial investors and institutional investors appears to have weighed on sentiment. The lock-up expiry also coincided with weakening investment sentiment across biotech stocks, adding to short-term selling pressure.</p> <p contents-hash="175493f87a6a758758aa8ce9c51de8ad23e8777ce03d688ea62396e8f7e010bd" dmcf-pid="2dW6pmSrOE" dmcf-ptype="general">“There are no special internal issues or separate negative factors at the company,” an Aimed Bio official said. “As the lock-up expired today, some profit-taking appears to have emerged amid weak biotech investor sentiment.”</p> <p contents-hash="099c399d45025e9a19d4977b7bb47d31633fb659468d7a260d91e0d55f986e74" dmcf-pid="VJYPUsvmmk" dmcf-ptype="general"><strong>ImmuneOncia falls below rights offering price, down 25% in four sessions</strong></p> <p contents-hash="3859821c095b519a9a0eb2842958c825d962cbd4633a3b974db4bbc99a37e284" dmcf-pid="fiGQuOTsEc" dmcf-ptype="general">ImmuneOncia came under heavy selling pressure after its share price fell below the final issue price for its rights offering.</p> <p contents-hash="f6f29ebf66528f700a9a5e652f558ec7a9705169ec5d656ecf43c7f934c639b3" dmcf-pid="4g5eBlGhEA" dmcf-ptype="general">ImmuneOncia’s stock has dropped 28% over the past four trading sessions, from 6,150 won to 4,425 won. On June 4, the stock closed at 4,425 won, down 825 won, or 15.71%, from the previous session, falling below the final rights offering price of 4,860 won. Trading volume surged to 1,883,495 shares, about 5.3 times the average of roughly 355,000 shares over the preceding three sessions.</p> <p contents-hash="81a70e4cb5ad61477d77a15ba27ef616041f21f3d6e90e87a3fd3d96fae3ba45" dmcf-pid="8a1dbSHlrj" dmcf-ptype="general">ImmuneOncia previously pushed ahead with a 120 billion won rights offering through a shareholder allocation followed by a public offering of forfeited shares less than a year after its listing. The move came just nine months after the company raised 32.9 billion won through its IPO in May last year.</p> <p contents-hash="f77ae9a46a8e5a887eed959169142f7b555380cbf7902931d1df27a3f1d7da34" dmcf-pid="6NtJKvXSIN" dmcf-ptype="general">Controversy also arose after it became known that Yuhan Corporation, ImmuneOncia’s largest shareholder, initially planned to participate at a level of around 10 billion won. Yuhan later raised its participation amount to 15 billion won, but criticism continued that its participation rate remained low relative to its allocated shares.</p> <p contents-hash="5e9ec8a275f210c9ddef7efe2947c7ec0ffba8442974e62c408aae91a75f7106" dmcf-pid="PjFi9TZvIa" dmcf-ptype="general">ImmuneOncia recorded a 104.29% subscription rate from existing shareholders, avoiding a public offering of forfeited shares. However, as the final issue price was lowered from the planned 7,130 won to 4,860 won, the expected proceeds fell 32% from 120 billion won to 81.8 billion won.</p> <p contents-hash="0c431a28c0dd33505b174f69a48e5d6c08ca89eee60be8b713bc8e3b828e6672" dmcf-pid="QA3n2y5Twg" dmcf-ptype="general">Concerns are now growing in the market over whether ImmuneOncia can proceed as planned with preparations for commercialization of its immuno-oncology candidate IMC-001 using the 81.8 billion won in proceeds. The company has said it has no plans for additional fundraising, but uncertainty remains over future funding needs, as its commercialization target is set for 2031. In particular, concerns have been raised because the company’s funding plan assumes a licensing deal next year.</p> <p contents-hash="0359afaa97cae120d43377bac72243828487e9305f281ec211f173a63ab6c873" dmcf-pid="xc0LVW1ywo" dmcf-ptype="general">“Because a licensing deal is not a confirmed event, it is difficult for the market to fully trust a plan that relies on filling a funding gap through a license-out,” a financial investment industry official said.</p> <p contents-hash="e723b22381e5c26ff211bb0e8892e13f90018d8aa557448e033d232e0296b292" dmcf-pid="yuN1IMLxrL" dmcf-ptype="general">Edaily contacted ImmuneOncia multiple times to reconfirm the background of the recent share price plunge and the company’s post-rights offering fund execution plan, but was unable to reach the company by phone.</p> <p contents-hash="d28b21cb06ed4ade552756b3ae4bc1346681ffb394597261a58d1f0594859fa7" dmcf-pid="W7jtCRoMEn" dmcf-ptype="general">김새미 (bird@edaily.co.kr) </p> </section> </div> <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p>
댓글등록
댓글 총
0
개
맨위로
이번주
포인트
랭킹
매주 일요일 밤 0시에 랭킹을 초기화합니다.
1
4,000
상품권
2
3,000
상품권
3
2,000
상품권
업체홍보/구인
더보기
[구인]
유투브 BJ 구인중이자나!완전 럭키비키자나!
[구인]
에카벳에서 최대 조건으로 부본사 및 회원님들 모집합니다
[구인]
카지노 1번 총판 코드 내립니다.
[구인]
어느날 부본사 총판 파트너 모집합니다.
[구인]
고액전용 카지노 / 헬렌카지노 파트너 개인 팀 단위 모집중 최고우대
지식/노하우
더보기
[카지노 노하우]
혜택 트렌드 변화 위험성 다시 가늠해 보기
[카지노 노하우]
호기심이 부른 화 종목 선택의 중요성
[카지노 노하우]
카지노 블랙잭 카드 조합으로 히트와 스탠드를 결정하는 방법
[카지노 노하우]
흥부가 놀부될때까지 7
[카지노 노하우]
5월 마틴하면서 느낀점
판매의뢰
더보기
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
[제작판매]
html5웹미니게임제작 해시게임제작 카드포커게임제작 스포츠토토 카지노 슬롯 에볼루션 토지노 솔루션분양임대재작
포토
더보기
채팅하기